Zenotech Laboratories (BSE: ZENOTECH) is loss-making over the last 12 months, losing ₹4.25 Cr, so a P/E ratio does not apply. Its share price on 6 Nov 2026 was ₹38.44, 27% below its 52-week high. Sales grew 1.0% a year over 3 years. It is a small-cap company with a market cap of ₹235 Cr, ranked 92nd of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 27% over the past year.
- ₹38.50
- ₹38.79
- ₹38.01
- ₹38.41
- 3.5K
Health check
- ReturnsBehind
−27.5% over a year, better than 0 of 7 peers.
- Price tagLoss-making
Earnings were negative over the last 12 months.
- GrowthUnder pressure
Sales +1.0% a year over 3 years, but loss-making now.
- ProfitabilityNegative
ROCE -1.9% vs peer median 17.9%.
- Balance sheetn/a
Balance sheet figures aren’t reported.
- Red flags3 to check
Loss-making over the last twelve months.
Small cap
Defensive
Key metrics
- Market cap
- ₹235 Cr
- Small cap
- P/E
- n/a
- Industry 28.7
- Price to book
- 2.56
- Peers 4.99
- Dividend yield
- 0.00%
- ROE
- −4.5%
- Peers 14.7%
- ROCE
- −1.9%
- Peers 17.9%
- Debt to equity
- n/a
- Debt ₹0.00 Cr
- EPS (TTM)
- −₹0.70
- OPM (TTM)
- 9.0%
- Net margin −11.5%
- Sales growth
- −40.1%
- Latest quarter vs a year ago
- Profit growth
- n/a
- Year-ago quarter not reported
- Price to sales
- 6.34
- EV/EBITDA 52.3
Strengths and risks
Strengths
- Positive operating cash flow in each of the last 4 years.
Risks to check
- Loss-making over the last twelve months.
- Return on equity is low at −4.5%.
- Quarterly sales down 40.1% on a year ago.
About Zenotech Laboratories
Zenotech Laboratories Limited manufactures and markets pharmaceutical specialty generic injectables in the oncology and anesthesiology markets in India. It offers contract manufacturing services for parenteral depot formulations, ophthalmic, oncology oral and injectables, and general injectables. The company also leases out its biotech facility and equipment. Zenotech Laboratories Limited was incorporated in 1989 and is based in Hyderabad, India.
- Headquarters
- Hyderabad
- Employees
- 264
- Sector
- Healthcare
- ISIN
- INE486F01012
- Website
- zenotechlab.com
Price range
- Avg volume (3M)
- 8.5K
- 1-year return
- minus 27.5%
- From 52-week high
- minus 27.1%
Peers · Drug Manufacturers - Specialty & Generic
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMASun Pharmaceutical Industries | 1,860.00 | plus 1.69% | 4,46,276 | 40.7 | 4.99 | 17.9% | 13.1% | 28.2% | 10.4% | 10.6% | 0.86% | plus 8.2% |
| DIVISLABDivi's Laboratories | 10,320.50 | plus 1.78% | 2,73,977 | 93.6 | 16.35 | 19.0% | 16.2% | 34.9% | 11.0% | 12.1% | 0.29% | plus 49.0% |
| TORNTPHARMTorrent Pharmaceuticals | 4,750.00 | plus 0.85% | 1,80,675 | 80.2 | 9.83 | 9.1% | 15.7% | 33.7% | 13.3% | 20.2% | 0.80% | plus 31.7% |
| LAURUSLABSLaurus Labs | 2,340.00 | minus 0.26% | 1,26,433 | 94.4 | 20.86 | 19.5% | 24.0% | 30.4% | 3.8% | 4.0% | 0.09% | plus 138.6% |
| ZYDUSLIFEZydus Lifesciences | 1,197.90 | plus 0.41% | 1,19,491 | 28.6 | 4.29 | 19.0% | 14.7% | 26.2% | 16.5% | 37.0% | 0.08% | plus 22.8% |
| DRREDDYDr. Reddy's Laboratories | 1,373.00 | plus 0.51% | 1,14,462 | 40.9 | 2.96 | 14.2% | 7.3% | 15.9% | 11.0% | −1.7% | 0.58% | plus 13.8% |
| CIPLACipla | 1,411.00 | plus 0.49% | 1,13,993 | 39.4 | 3.22 | 14.9% | 8.3% | 17.3% | 7.2% | 11.5% | 0.92% | minus 6.6% |
| ZENOTECHZenotech Laboratories | 38.44 | plus 0.08% | 235 | – | 2.56 | – | −4.5% | −62.7% | – | – | 0.00% | minus 27.5% |
| Median of 7 peers | – | 0.51% | 1,26,433 | 40.9 | 4.99 | 17.9% | 14.7% | 28.2% | 11.0% | 11.5% | 0.58% | 22.8% |
Quarterly results
| ₹ Cr | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Sep 26 |
|---|---|---|---|---|---|
| 10.2 | 11.8 | 8.9 | 9.6 | 6.1 | |
| 7.9 | 7.6 | 8.7 | 8.7 | 8.2 | |
| 2.3 | 4.3 | 0.2 | 0.9 | −2 | |
| 22.4% | 36.1% | 1.9% | 9.0% | −33.1% | |
| 0.7 | 0.4 | 0.6 | 0.4 | 0.4 | |
| 1.8 | 1.8 | 1.8 | 1.9 | 1.8 | |
| 0 | −0.3 | 0.1 | – | – | |
| 1.3 | 2.6 | −0.9 | −0.6 | −3.4 | |
| 166.5% | 25.6% | −236.8% | 24.2% | 24.8% | |
| −0.8 | 1.9 | −3.2 | −0.5 | −2.6 | |
| -0.14 | 0.32 | -0.52 | -0.07 | -0.42 |
Profit & loss
- Sales CAGR 3Y
- +1.0%
- ROE
- −4.5%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 38.4 | 36.8 | 39 | 39.6 | |
| – | minus 4.1% | +6.0% | +1.5% | |
| 21.7 | 23.6 | 28.8 | 34.3 | |
| 16.6 | 13.2 | 10.1 | 5.2 | |
| 43.4% | 35.9% | 26.0% | 13.2% | |
| 5.1 | 5.1 | 5.6 | 6.3 | |
| 0.1 | – | – | – | |
| 7.2 | 7.1 | 7 | 7.1 | |
| 0 | −0 | 1.9 | −0.2 | |
| 14.5 | 11.1 | 10.7 | 4.2 | |
| 20.1% | 25.5% | 47.5% | 125.6% | |
| 11.6 | 8.3 | 5.6 | −1.1 | |
| – | minus 28.4% | minus 32.4% | minus 119.1% | |
| 1.90 | 1.36 | 0.92 | -0.18 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 61 | 61 | 61 | 61 | |
| 21.2 | 29.5 | 35.1 | 34.1 | |
| 18.6 | 15.7 | 14.7 | 16 | |
| 101 | 106 | 111 | 111 | |
| 70.4 | 67.5 | 64.5 | 66 | |
| 5 | 2 | 3.7 | 3.7 | |
| – | 0 | 0.1 | 1.3 | |
| 11.1 | 19.7 | 26.7 | 30.4 | |
| 14.4 | 17 | 15.8 | 9.7 | |
| 101 | 106 | 111 | 111 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 20.7 | 11.8 | 9.5 | 10.2 | |
| −5.8 | −21.2 | 15.2 | −6.5 | |
| −6.1 | – | – | – | |
| 8.7 | −9.3 | 24.8 | 3.7 | |
| −6.2 | −4.2 | −3.9 | −8.3 | |
| 14.4 | 7.6 | 5.6 | 1.9 |
Shareholding pattern
This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.
Major shareholders
Filings & events
News
No recent news coverage found.